Danaher reports earnings, revenue increases in Q2

By The Science Advisory Board staff writers

July 23, 2021 -- Danaher announced earnings and revenue increases for its second quarter of 2021 (end-July 2).

Danaher said that revenues increased 36.5% year-over-year to $7.2 billion, while net earnings were $1.7 billion, an 84% year-over-year increase from the 2020 period.

Rainer Blair, company president and CEO, said broad-based strength across the portfolio helped the company deliver on core revenue growth, as well as growth in earnings per share and cash flow generation.

Danaher to acquire Aldevron in deal valued at $9.6B
Danaher announced it has signed a deal to buy DNA and messenger RNA manufacturer Aldevron for approximately $9.6 billion. Aldevron will operate as...
Danaher acquires Precision NanoSystems
Danaher has acquired Precision NanoSystems, a Canadian developer of genetic medicines including messenger RNA vaccines.
Danaher announces chief executive transition
Danaher announced on May 6 that Executive Vice President Rainer Blair will succeed Thomas Joyce Jr. as president and CEO when Joyce retires on September...

Copyright © 2021 scienceboard.net

Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter